BridgeBio Pharma's earnings have been declining at an average annual rate of -7.3%, while the Biotechs industry saw earnings growing at 17.9% annually. Revenues have been growing at an average rate of 49% per year.
Key information
-7.30%
Earnings growth rate
2.43%
EPS growth rate
Biotechs Industry Growth
-14.59%
Revenue growth rate
48.98%
Return on equity
n/a
Net Margin
-144.39%
Next Earnings Update
07 May 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BridgeBio Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
DB:2CL Revenue, expenses and earnings (USD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
502
-725
531
452
30 Sep 25
354
-797
451
466
30 Jun 25
236
-776
383
473
31 Mar 25
127
-668
313
477
31 Dec 24
222
-536
289
506
30 Sep 24
218
-439
242
506
30 Jun 24
219
-454
209
511
31 Mar 24
219
-538
185
504
31 Dec 23
9
-643
151
456
30 Sep 23
9
-613
135
416
30 Jun 23
6
-573
130
384
31 Mar 23
78
-425
131
385
31 Dec 22
78
-481
143
399
30 Sep 22
89
-491
166
431
30 Jun 22
91
-509
181
443
31 Mar 22
71
-596
191
436
31 Dec 21
70
-563
189
451
30 Sep 21
57
-535
172
419
30 Jun 21
63
-495
162
407
31 Mar 21
9
-520
154
391
31 Dec 20
8
-449
146
337
30 Sep 20
22
-402
143
304
30 Jun 20
41
-346
131
268
31 Mar 20
41
-291
110
233
31 Dec 19
41
-261
94
210
30 Sep 19
27
-226
74
204
30 Jun 19
0
-197
61
180
31 Mar 19
0
-155
54
151
31 Dec 18
0
-131
44
140
Quality Earnings: 2CL is currently unprofitable.
Growing Profit Margin: 2CL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2CL is unprofitable, and losses have increased over the past 5 years at a rate of 7.3% per year.
Accelerating Growth: Unable to compare 2CL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2CL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (45%).
Return on Equity
High ROE: 2CL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/03 17:21
End of Day Share Price
2026/04/30 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BridgeBio Pharma, Inc. is covered by 37 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.